drugset / Trial / NCT03330327

Molar Potency Study of HM12470 in Healthy Subjects

NCT03330327 ↗

Phase 1 Completed 56 enrolled Hanmi Pharmaceutical Company Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 study to assess and compare molar potency of HM12470 and regular human insulin in healthy subjects.

Timeline

Start
2015-03-30
Primary completion
2017-08-17
Completion
2017-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject HM12470 Unknown — Intravenous

Indications

No indication recorded.